Toronto, Canada, October 10th 2019 - IBA (Ion Beam Applications S.A., EURONEXT), a leading provider of solutions for the diagnosis and treatment of cancer, and the Azrieli Centre for Neuro-Radiochemistry at CAMH (Centre for Addition and Mental Health), one of North America’s top mental health hospitals and research centers, announce the initiation of a long-term collaboration agreement. The partnership will aim to promote the field of nuclear medicine by collectively building a strong R&D and clinical program.
The research will focus on discovering, developing and testing of new Positron Emission Tomography (PET) imaging agents for the early detection of diseases and conditions in the fields of neurology, oncology, inflammation, etc. SyntheraÒ, IBA’s radiosynthesizer platform, will be used in combination with the already installed IBA cyclotron.The formal agreement outlines efforts to increase collaboration, training, and effectiveness starting from the process of radiopharmaceutical discovery to the final commercialization of promising candidates.
“CAMH and IBA share a deep commitment to further strengthening the world’s Nuclear Medicine field in the most creative and effective way.” Said Bruno Scutnaire, President at IBA, Radiopharma Solutions.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
“The partnership between IBA and CAMH is an example of building a bridge between an industrial and an academic institution. This will create exciting growth opportunities for both parties. Innovation is best realized with all doors and minds opened to new possibilities.” Said Neva Lazarova, Ph.D., MBA, Director of Collaborations and Innovation- Chemistry at IBA, Radiopharma Solutions.
“This funding will create a formal collaboration between our Azrieli Centre for Neuro-Radiochemistry at CAMH in Toronto, where, we already house an IBA Cyclotron for our human PET radiopharmaceutical production. This new partnership will enable us to apply cutting-edge radiochemistry methods from CAMH and new technologies from IBA to prepare unique diagnostic tools for positron emission tomography (PET) imaging studies in patients suffering from brain health illnesses and other diseases” Said Neil Vasdev, Ph.D., Director of the Azrieli Centre for Neuro-Radiochemistry & Director of the CAMH Research Imaging Centre. Dr. Vasdev is also the endowed Azrieli Chair in Brain and Behaviour at the University of Toronto and holds the Canada Research Chair in Radiochemistry and Nuclear Medicine.